NASDAQ:NARI - Inari Medical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $129.40
  • Forecasted Upside: 39.62 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$92.68
▲ +2.67 (2.97%)
1 month | 3 months | 12 months
Get New Inari Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NARI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NARI

Average Price Target: $129.40
▲ +39.62% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Inari Medical in the last 3 months. The average price target is $129.40, with a high forecast of $135.00 and a low forecast of $125.00. The average price target represents a 39.62% upside from the last price of $92.68.

Buy

The current consensus among 5 polled investment analysts is to buy stock in Inari Medical.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2021Morgan StanleyBoost Price TargetOverweight$126.00 ➝ $129.00High
5/12/2021Canaccord GenuityBoost Price TargetBuy$129.00 ➝ $132.00High
3/16/2021Canaccord GenuityReiterated RatingBuy$94.00 ➝ $129.00Medium
3/10/2021Canaccord GenuityBoost Price TargetBuy$94.00 ➝ $129.00N/A
3/10/2021SVB LeerinkBoost Price TargetOutperform$116.00 ➝ $126.00High
3/10/2021Wells Fargo & CompanyBoost Price TargetOverweight$112.00 ➝ $125.00High
3/10/2021Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $126.00High
3/10/2021BTIG ResearchBoost Price TargetBuy$125.00 ➝ $135.00High
1/21/2021BTIG ResearchBoost Price TargetBuy$92.00 ➝ $110.00Low
1/20/2021Wells Fargo & CompanyBoost Price TargetOverweight$79.00 ➝ $112.00Low
12/15/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$79.00Medium
11/18/2020BTIG ResearchInitiated CoverageBuy$92.00High
11/13/2020Morgan StanleyBoost Price TargetOverweight$76.00 ➝ $85.00High
11/13/2020SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $90.00High
10/29/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$66.00 ➝ $76.00Low
9/28/2020SVB LeerinkInitiated CoverageOutperform$80.00Medium
8/12/2020Morgan StanleyBoost Price TargetEqual Weight$52.00 ➝ $66.00High
8/12/2020Canaccord GenuityBoost Price TargetBuy$60.00 ➝ $73.00High
6/19/2020Canaccord GenuityInitiated CoverageBuy$60.00Low
6/16/2020Bank of AmericaInitiated CoverageNeutral$56.00Low
6/16/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$49.00Low
6/16/2020Morgan StanleyInitiated CoverageEqual Weight$52.00Low
(Data available from 6/20/2016 forward)
Inari Medical logo
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It offers ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $92.68
Low: $89.08
High: $93.78

50 Day Range

MA: $95.47
Low: $79.62
High: $114.85

52 Week Range

Now: $92.68
Low: $44.59
High: $127.42

Volume

654,945 shs

Average Volume

590,163 shs

Market Capitalization

$4.60 billion

P/E Ratio

421.29

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Inari Medical?

The following sell-side analysts have issued stock ratings on Inari Medical in the last year: BTIG Research, Canaccord Genuity, Morgan Stanley, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NARI.

What is the current price target for Inari Medical?

5 Wall Street analysts have set twelve-month price targets for Inari Medical in the last year. Their average twelve-month price target is $129.40, suggesting a possible upside of 39.6%. BTIG Research has the highest price target set, predicting NARI will reach $135.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $125.00 for Inari Medical in the next year.
View the latest price targets for NARI.

What is the current consensus analyst rating for Inari Medical?

Inari Medical currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NARI will outperform the market and that investors should add to their positions of Inari Medical.
View the latest ratings for NARI.

What other companies compete with Inari Medical?

How do I contact Inari Medical's investor relations team?

Inari Medical's physical mailing address is 9 Parker Suite 100, Irvine CA, 92618. The company's listed phone number is 877-923-4747 and its investor relations email address is [email protected] The official website for Inari Medical is www.inarimedical.com.